At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Eletriptan commercial tablet +3 moredrug
Likely dose
Eletriptan commercial tablet 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Single And Repeat Dose Randomized Crossover Study To Estimate The Pharmacokinetics And Safety Of Eletriptan Hydrobromide Tablets In Healthy Korean Male Subjects
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Jun 8, 2010·Updated Jan 28, 2021
In Brief
A Phase 1 clinical trial evaluating Eletriptan commercial tablet for Healthy. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The hypothesis of this study is that Korean subjects have similar Pharmacokinetics (PK) characteristics to those seen in other populations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSouth Korea
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2010
Enrollment StartJul 2010
Primary CompletionJul 2010
TodayJul 2026
First PostedJun 8, 2010
Enrollment StartJul 1, 2010
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 16.1 years ago
Interventions
Eletriptan commercial tabletdrug
20 mg tablet, single dose
Eletriptan commercial tabletdrug
40 mg tablet, single dose of 1 X 40 mg
Eletriptan commercial tabletdrug
40 mg tablet, single dose of 2 X 40 mg
Eletriptan commercial tabletdrug
40 mg tablet, 1 X 40 mg given two times: the second 2 hours after the first